A Protein Kinase Inhibitor, Fasudil (AT‐877): A Novel Approach to Signal Transduction Therapy
Authors:
- 1 March 1998
- journal article
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 16 (1) , 76-87
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North AmericaJournal of Neurosurgery, 1997
- Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New ZealandJournal of Neurosurgery, 1996
- Getting down to specificsNature, 1995
- Pretreatment of transient focal cerebral ischemia in rats with the calcium antagonist AT877.Stroke, 1994
- Effects of vasopressin and oxytocin on canine cerebral circulation in vivoJournal of Neurosurgery, 1992
- Pharmacology of Protein Kinase InhibitorsAnnual Review of Pharmacology and Toxicology, 1992
- Pharmacology Of Protein Kinase InhibitorsAnnual Review of Pharmacology and Toxicology, 1992
- Inhibition of myosin light chain phosphorylation in cultured smooth muscle cells by HA1077, a new type of vasodilatorBiochemical and Biophysical Research Communications, 1990
- The Function of Myosin and Myosin Light Chain Kinase Phosphorylation in Smooth MuscleAnnual Review of Pharmacology and Toxicology, 1985
- Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid HemorrhageNew England Journal of Medicine, 1983